45 results on '"Mohebi, Reza"'
Search Results
2. Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction
3. Isovolumic Contraction Velocity In Heart Failure With Reduced Ejection Fraction And Effect Of Sacubitril/valsartan: The PROVE-HF Study
4. Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level
5. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
6. Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction
7. Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
8. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
9. Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan
10. CLINICAL PROFILING OF END-STAGE HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE NATIONAL READMISSION DATABASE
11. WHY MEASURE NT-PROBNP SERIALLY IN CHRONIC HEART FAILURE? MECHANISTIC ASSOCIATIONS OF NATRIURETIC PEPTIDE SLOPE FOLLOWING INITIATION OF SACUBITRIL/VALSARTAN
12. DEFINING THE PREVALENCE AND CHARACTERISTICS OF CORONARY ARTERY DISEASE AMONG PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION USING CT-FFR (DEFINE TYPE 2 MI)
13. ATRIAL FIBRILLATION PRIOR TO HEART FAILURE ONSET IS ASSOCIATED WITH ADVERSE OUTCOMES IN PATIENTS REGARDLESS OF LEFT VENTRICULAR EJECTION FRACTION
14. HOW DOES SEX AFFECT ETIOLOGY OF HEART FAILURE? DIFFERENCES BETWEEN WOMEN AND MEN IN THE PRECISION MEDICINE DATABASE FOR AMBULATORY HEART FAILURE PATIENTS (PREFER-HF) STUDY
15. INFLAMMATION ACROSS UNIVERSAL DEFINITION OF HEART FAILURE STAGES: RESULTS OF CASABLANCA STUDY
16. Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
17. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
18. Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography
19. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
20. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
21. Relation of High-Sensitivity Cardiac Troponin I and Obstructive Coronary Artery Disease in Patients Without Acute Myocardial Infarction
22. Reply
23. Reply
24. Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI
25. FORECASTING TRENDS IN CARDIOMETABOLIC RISK FACTORS IN THE UNITED STATES: ESTIMATES BASED ON THE 2020 CENSUS
26. FUTURE OF CARDIOVASCULAR DISEASE IN THE UNITED STATES: ESTIMATES BASED ON THE 2020 CENSUS
27. PERFORMANCE OF A MULTIPLE PROTEIN BIOMARKER PANEL FOR PREDICTION OF CARDIOVASCUALR EVENTS IN PATIENTS WITH DIABETES MELLITUS
28. Obesity-Mediated Disruption of Natriuretic Peptide–Blood Pressure Rhythms
29. LONG-TERM CLINICAL IMPACT OF CONTRAST-ASSOCIATED ACUTE KIDNEY INJURY FOLLOWING PCI AN ADAPT-DES SUB-STUDY
30. Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia
31. EPICARDIAL ADIPOSE TISSUE EVALUATED BY CARDIAC MAGNETIC RESONANCE PREDICTS ADVERSE OUTCOMES IN HEART FAILURE PATIENTS
32. EFFECT OF SGLT2 INHIBITORS ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS
33. PRETREATMENT WITH SGLT2 INHIBITORS AMELIORATES CONTRAST-INDUCED NEPHROPATHY
34. Oxygen consumption and carbon-dioxide recovery kinetics in the prediction of coronary artery disease severity and outcome
35. Percentile categorization of QT interval as an approach for identifying adult patients at risk for cardiovascular death
36. Abrasion resistance of alkali-activated slag concrete designed by Taguchi method
37. Obesity Paradox and Risk of Mortality Events in Chronic Kidney Disease Patients: A Decade of Follow-up in Tehran Lipid and Glucose Study
38. Application of alkali-activated slag concrete in railway sleepers
39. Wrist circumference as a novel predictor of hypertension and cardiovascular disease: results of a decade follow up in a West Asian cohort
40. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study
41. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?
42. Lipid profile components and incident cerebrovascular events versus coronary heart disease; the result of 9 years follow-up in Tehran Lipid and Glucose Study
43. Effects of Obesity on the Impact of Short-Term Changes in Anthropometric Measurements on Coronary Heart Disease in Women
44. Change in general and central adiposity measures in prediction of incident dysglycemia; Tehran Lipid and Glucose Study
45. Electrocardiographic abnormalities improve classification of coronary heart disease risk in women: Tehran Lipid and Glucose Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.